HMOX1 and ovarian cancer: Conversely, apatinib, a new oral tyrosine kinase inhibitor that targets VEGF signaling, can inhibit the Nrf2–HO-1 pathway to exhaust the cellular glutathione reservoir and thereby significantly elevate intracellular ROS levels, leading to apoptosis and autophagy in ovarian cancer cells [148].